Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
Sponsor: Retina Research Institute, LLC
A PHASE4 clinical study on Age Related Macular Degeneration, this trial is ongoing. The trial is conducted by Retina Research Institute, LLC and has accumulated 10 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE4
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Aug 2017 — Nov 2017 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Retina Research Institute, LLC
- Valley Retina Institute
For direct contact, visit the study record on ClinicalTrials.gov .